We and others have demonstrated that blocking the GLP1RA-induced GFRAL→CGRPelPBN pathway with another incretin, glucose-dependent insulinotropic polypeptide, removes the aversive element of treatment without reversing the anorexia19,25, which has important implications in the development of obesity drugs. This evidence concerns the gene GIP and obesity disorder.